Executive leadership at BioNexus Gene Lab.
Board of directors at BioNexus Gene Lab.
Research analysts covering BioNexus Gene Lab.
Recent press releases and 8-K filings for BGLC.
BioNexus Gene Lab Corp. Launches Regional Deployment of VitaGuard™ MRD Platform
BGLC
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- BioNexus Gene Lab Corp. (BGLC) announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform on January 28, 2026.
- This phase aims to transition VitaGuard™ into a scalable oncology infrastructure across Southeast Asia, designed to challenge high-cost legacy monitoring systems that can exceed $3,000 per test.
- The company's strategic roadmap for 2026 includes phased regional deployment, workflow integration with healthcare providers, and leveraging Fidelion Diagnostics Pte. Ltd. as the exclusive vehicle for international commercialization outside Greater China.
- The deployment is also intended to serve as a "Data-Ignition Phase" to generate molecular datasets for the development of AI-assisted oncology tools calibrated for regional genomic profiles.
3 days ago
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more